30 months relapse-free survival, overall survival, and long-term toxicity update of (neo)adjuvant ipilimumab (ipi) plus nivolumab (nivo) in macroscopic stage III melanoma (OPACIN trial)

Author(s):: Rozeman, E.A.; Sikorska, K.; Wiel, B.A.V. de; Fanchi, L.F.; Krijgsman, O.; Thienen, H.V. van; Pronk, L.M.; Broeks, A.; Grijpink-Ongering, L.; Meulen, S. ter; Bruining, A.; Klop, W.M.C.; Tinteren, H. van; Peeper, D.; Haanen, J.B.A.G.; Akkooi, A.C.J. van; Schumacher, T.N.; Blank, C.U.

Published: 2018
Publication type: Article / Letter to editor

Date issued: 2018-12-31
Language: English
Is part of: Annals of Oncology (2018), Vol. 29, p. 42-42
hdl: 1887/4105261
doi: 10.1093/annonc/mdy511.002
URL: https://www.sciencedirect.com/science/article/pii/S0923753419327590?via%3Dihub